Dow expands pharmaceutical presence

Dow is expanding its presence in the pharmaceutical market, uniting several of its existing offerings under the Dowpharma portfolio to reflect the sector's need for a single source contract manufacturer of both pharma and biopharma technologies.

The new Dowpharma portfolio covers a full spectrum of development and manufacturing services for the production of synthetic pharmaceutical intermediates and active ingredients. It includes chiral technology, nucleic acid medicines manufacturing, biopharmaceutical contract development and production by microbial and plant-based systems, radiopharmaceutical development, and drug delivery including solubilisation services.

The announcement follows a series of strategic moves made since the company first emerged as a major contract manufacturing organisation (CMO) in the pharmaceutical services market just over two years ago. 'Customers have told us they need a CMO with a full range of skills as well as demonstrated performance in project execution, regulatory compliance, and technical expertise to help their drugs progress to commercialisation, and we can provide this,' said Nick Hyde, business director, Dowpharma.

The new strategic mix reflects Dow's commitment to provide a wide array of capabilities and expertise, delivered seamlessly, and tailored to each customer's needs. 'By listening carefully, and through meaningful discussion, we will deliver solutions to optimise the products and processes of both large and small pharmaceutical companies as well as emerging companies that have everything riding on a single molecule,' said Hyde.